证券日报网讯1月20日，蔚蓝生物（603739）在互动平台回答投资者提问时表示，截至目前，公司业务 以国内市场为主，国内业务收入占比约为92%。公司海外市场主要包括美国、欧盟、菲律宾、埃及、巴 西等。其中，公司对欧盟市场的销售主要由境内主体直接向欧盟客户实现销售，相关收入占比很低。公 司将严格按照《上海证券交易所股票上市规则》等相关规定进行公告，及时履行信息披露义务，有关信 息请以公司在上海证券交易所网站披露的相关公告为准。 ...

证券代码：603739 证券简称：蔚蓝生物 公告编号：2026-002 青岛蔚蓝生物股份有限公司 关于为全资子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 被担保人名称 | 本次担保金额 | | 实际为其提供的 担保余额（不含本 | | 是否在前期预计 | 本次担保是否有 反担保 | | --- | --- | --- | --- | --- | --- | --- | | | | | 次担保金额） | | 额度内 | | | 青岛蔚蓝生物集团 有限公司 | 4,000.00 | 万元 | 25,410.48 | 万元 | 是 | 否 | | 潍坊康地恩生物科 技有限公司 | 3,000.00 | 万元 | 7,153.98 | 万元 | 是 | 否 | | 青岛蔚蓝动物保健 集团有限公司 | 1,350.00 | 万元 | 4,980.00 | 万元 | 是 | 否 | 担保对象及基本情况 累计担保情况 | 对外担保逾期的累计金额（万元） | 0.00 | | --- | --- ...

Group 1 - Shoukai Co. achieved a signed area of 125.72 million square meters and a signed amount of 17.845 billion yuan in 2025 [1] - Tongda Hai expects a net loss for the year 2025 [2] - Jiuri New Materials' subsidiary has entered the trial production phase for a project with an annual capacity of 350 tons of hydroxy ketone [3] Group 2 - Jixin Technology's shareholder plans to reduce their stake by up to 1% [4] - Fulai New Materials received approval from the CSRC for a stock issuance [5] - Yaqi International plans to sign a strategic cooperation framework agreement with Zhongnong Holdings [6] Group 3 - Sanwei Co.'s controlling shareholder plans to transfer up to 5.10% of shares [7] - Lekai Film's subsidiary plans to invest 97.6675 million yuan in a TAC functional film production line [8] - China Power Construction's subsidiary signed two major contracts totaling approximately 15.589 billion yuan [9] Group 4 - Shunhao Co. plans to increase its investment in a subsidiary by 74.98 million yuan [10] - Jieneng Wind Power reported a cumulative power generation of 12.417 billion kWh in 2025, a year-on-year increase of 1.43% [11] - Zhongjian Technology's H-share issuance application has been accepted by the CSRC [12] Group 5 - Hendi Pharmaceutical expects a net profit decrease of 57.4% to 66.14% in 2025 [13] - Haopeng Technology anticipates a net profit increase of 113.69% to 141.09% in 2025 [14] - Lingang Co. expects a net loss of 1.45 billion to 1.67 billion yuan in 2025 [15] Group 6 - Chuan Investment Energy reported a cumulative power generation of 6.627 billion kWh in 2025, a year-on-year increase of 13.85% [16] - Tengyuan Cobalt expects a net profit increase of 50.02% to 69.87% in 2025 [17] - Huazhi Jie plans to repurchase shares worth 30 million to 50 million yuan [18] Group 7 - Opto has won a bid for a 120 million yuan project from GoerTek [19] - Shanghai Construction reported a new contract amount of 252.942 billion yuan in 2025, a year-on-year decrease of 34.98% [20] - Hangfa Control expects a net profit decrease of 52.02% to 58.02% in 2025 [22] Group 8 - Shimao Energy is planning a change in control and will continue to suspend trading [23] - Shenwan Hongyuan Securities received approval for a bond issuance of up to 60 billion yuan [24] - Jingjiawei signed a strategic cooperation letter of intent with Jing'an Technology [25] Group 9 - Pianzaihuang completed the first subject enrollment for a clinical trial of a new drug [26] - Placo's subsidiary received a new veterinary drug registration certificate [27] - Zhongli Co. plans to reduce its stake by up to 0.75% [28] Group 10 - Solar Energy received renewable energy subsidies of 3.318 billion yuan in 2025, a year-on-year increase of 142.9% [29] - Palm Co. has filed a lawsuit to recover 144 million yuan in project payments [30][31] - Yongjin Co. plans to invest 2.658 billion yuan in a new stainless steel project [32] Group 11 - BAIC Blue Valley plans to increase its stake by 14.5 million to 16.4 million yuan [33] - Lingyun Light's stock issuance application has been approved by the CSRC [34] - Hongbo New Materials expects a net loss in 2025 [35] Group 12 - Shanghai Pharmaceuticals received approval for the listing of a new antifungal drug [36] - Changjiang Electric reported a net profit of 34.167 billion yuan in 2025, a year-on-year increase of 5.14% [37] - Weilan Bio received a new veterinary drug registration certificate [38] Group 13 - Pingzhi Information's subsidiary is expected to win a procurement project worth approximately 37.5884 million yuan [39]

Market Overview - The chemical products sector experienced a decline of 0.29% on January 13, with Qiaoyuan Co. leading the drop [1] - The Shanghai Composite Index closed at 4138.76, down 0.64%, while the Shenzhen Component Index closed at 14169.4, down 1.37% [1] Top Performers - Huaheng Biological (688639) saw a significant increase of 13.79%, closing at 41.34 with a trading volume of 419,600 shares and a transaction value of 1.721 billion [1] - Chenghe Technology (688625) rose by 12.29%, closing at 62.32 with a trading volume of 109,000 shares and a transaction value of 672 million [1] - Kaisa Biological (688065) increased by 12.14%, closing at 62.24 with a trading volume of 177,800 shares [1] Underperformers - Qiaoyuan Co. (301286) fell by 8.67%, closing at 47.41 with a trading volume of 53,000 shares and a transaction value of 258 million [2] - Hangqing Co. (002430) decreased by 6.99%, closing at 32.06 with a trading volume of 311,600 shares [2] - Taihe Technology (300801) dropped by 6.72%, closing at 30.39 with a trading volume of 173,200 shares [2] Capital Flow - The chemical products sector saw a net outflow of 642 million from institutional investors and 357 million from retail investors, while retail investors had a net inflow of 999 million [2] - The capital flow data indicates a mixed sentiment among different investor types within the sector [2] Individual Stock Capital Flow - Duoliangduo (002407) had a net inflow of 224 million from institutional investors, while it experienced a net outflow of 1.09 billion from retail investors [3] - Wanhu Chemical (600309) saw a net inflow of 189 million from institutional investors, with a net outflow of 76.596 million from retail investors [3] - Yahua Group (002497) had a net inflow of 154 million from institutional investors, while retail investors experienced a net outflow of 17.488 million [3]

证券代码：603739 证券简称：蔚蓝生物 公告编号：2026-001 青岛蔚蓝生物股份有限公司 关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 作用与用途：用于预防鸡新城疫、H9 亚型禽流感、禽腺病毒病（I 群，4 型）、 鸡传染性法氏囊病。免疫产生期为 14 日，1～3 周龄雏鸡免疫期为 4 个月，3 周 龄及以上鸡免疫期为 6 个月。 用法与用量：肌肉或皮下注射。1～3 周龄雏鸡，每只 0.3ml；3 周龄及以上 鸡，每只 0.5ml。 根据《兽药管理条例》和《兽药注册办法》等的相关规定，经农业农村部审 查，批准青岛蔚蓝生物股份有限公司（以下简称"公司"）及全资子公司青岛动 保国家工程技术研究中心有限公司、青岛蔚蓝动物保健集团有限公司与其他单位 联合申报的"鸡新城疫、禽流感（H9 亚型）、禽腺病毒病（I 群，4 型）、传染性 法氏囊病四联灭活疫苗（La Sota 株+TA 株+LC 株+VP2 蛋白）"为三类新兽药，并 于近日核发了《新兽药注册证书》（农业农村部公告第 987 号）。 一、新兽药 ...

Group 1 - The animal vaccine sector experienced a decline of 0.04%, ranking among the top losers in the concept sector, with notable declines from companies such as Hengtong Co., BioShares, and Kanghua Bio [1] - Among the animal vaccine stocks, 9 companies saw price increases, with Dongfang Bio, KQ Bio, and Haili Bio leading the gains at 2.23%, 0.87%, and 0.77% respectively [1] - The sector faced a net outflow of 212 million yuan from main funds, with 14 stocks experiencing outflows, and 7 stocks seeing outflows exceeding 10 million yuan, led by Roniu Mountain with a net outflow of 82.38 million yuan [2] Group 2 - The top stocks with net outflows included BioShares, Hengtong Co., and Kanghua Bio, with net outflows of 41.91 million yuan, 41.77 million yuan, and 24.74 million yuan respectively [2] - Conversely, the stocks with the highest net inflows were Dabeinong, Haili Bio, and Guoyao Modern, with net inflows of 32.76 million yuan, 6.20 million yuan, and 3.24 million yuan respectively [2] - The trading data indicated that Roniu Mountain had a trading rate of 8.05% and a price drop of 1.05%, while Dongfang Bio had a trading rate of 1.46% and a price increase of 2.23% [3]

Group 1 - The core point of the news is that Qingdao Weilan Biological Co., Ltd. experienced a stock price increase of 5.02%, reaching 15.06 CNY per share, with a total market capitalization of 3.811 billion CNY [1] - The company, established on February 23, 2005, specializes in the research, production, and sales of enzyme preparations, microecology, and animal health products [1] - The revenue composition of the company includes enzyme preparations at 36.63%, animal health products at 22.60%, other businesses at 21.75%, microecology at 17.27%, and others at 1.76% [1] Group 2 - From the perspective of the top ten circulating shareholders, Guotai Fund holds a position in Weilan Biological, with its Guotai Zhongzheng Livestock Breeding ETF (159865) increasing its holdings by 673,200 shares, totaling 2.1108 million shares, which represents 0.83% of the circulating shares [2] - The Guotai Zhongzheng Livestock Breeding ETF (159865) was established on March 1, 2021, with a current scale of 6.097 billion CNY, and has recorded a year-to-date return of 0.4% [2] - The fund manager, Liang Xing, has a tenure of 9 years and 215 days, with the fund's total asset size at 30.617 billion CNY, achieving a best return of 1112.34% during the tenure [3]

证券代码：603739 证券简称：蔚蓝生物 公告编号：2025-057 青岛蔚蓝生物股份有限公司 关于公司 2026 年度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2025 年 12 月 26 日，公司召开第五届董事会第二十二次会议，审议通过了 《关于预计公司 2026 年度日常关联交易的议案》。根据《上海证券交易所股票上 市规则》《青岛蔚蓝生物股份有限公司章程》等的相关规定,公司无关联董事需对 本议案回避表决，所有董事一致同意通过该议案，且该议案无需提交公司股东会 审议。 （二）2025 年度日常关联交易预计和执行情况 2024 年 12 月 27 日，公司分别召开第五届董事会第十五次会议和第五届监 事会第九次会议，审议通过了《关于预计公司 2025 年度日常关联交易的议案》， 对公司 2025 年度日常关联交易情况进行了预计。2025 年度日常关联交易预计和 执行情况详见下表： 是否需要提交股东会审议：否 日常关联交易对上市公司的影响：本次日常关联交易预计为青岛蔚蓝生 物股份有 ...

Core Viewpoint - The company announced the approval of the expected daily related transactions for 2026, which will not require shareholder meeting review [1] Group 1: Company Transactions - In the period from January to November 2025, the company sold products worth 8.0795 million yuan to Beidahuang Baoquanling Agricultural and Animal Husbandry Development Co., Ltd. and its subsidiaries, which is below the expected amount of 15 million yuan due to market conditions [1] - For 2026, the company anticipates sales of enzyme preparations and other products amounting to 15 million yuan, representing 1.23% of the same type of business [1] - The pricing for these transactions will be based on market prices, ensuring that the company's independence is not affected [1]

证券代码：603739 证券简称：蔚蓝生物公告编号：2025-056 青岛蔚蓝生物股份有限公司 关于为全资子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 担保对象及基本情况 ■ ● 累计担保情况 ■ 一、担保情况概述 （二）内部决策程序 上述担保事项已经公司2025年4月25日召开的第五届董事会第十六次会议审议通过，并经公司于2025年5 月16日召开的2024年年度股东会批准。具体内容详见公司分别于2025年4月26日、2025年5月17日在上海 证券交易所网站披露的《青岛蔚蓝生物股份有限公司关于2025年度对外担保额度预计的公告》（公告编 号：2025-011）、《青岛蔚蓝生物股份有限公司2024年年度股东会决议公告》（公告编号：2025- 022）。 二、被担保人基本情况 ■ 三、担保协议的主要内容 1、债权人：中国光大银行股份有限公司青岛城阳支行 6、保证期间：自具体授信业务合同或协议约定的受信人履行债务期限届满之日起三年。 7、保证范围：受信人在主合同项下应向授信人偿还或 ...